– Yuqing Niu, CEO, Xingtera –
– Yuqing Niu, CEO, Xingtera –
Dr. Zhang Yan, the founder of Camray, and Dr. Dong Hu, the founder of iRock, both were selected in China’s “thousand talents program” for returnees in February 2015. Camray and iRock were funded by ChinaMaterialia as a lead investor.
China Materialia has invested in iRock Technologies, a high-technology company founded in 2010 in China by returnee, Dr. Hu Dong.
iRock Technologies provides digital special core analysis (SCAL) software and services to national and international oil companies. iRock leverage years of research from the Imperial College Consortium on Pore Scale Modeling to provide comprehensive reservoir insights that can affordably improve recovery factor for oil and gas companies worldwide. Sponsors of the Imperial Consortium include the UK Department of Trade and Industry, BG Group, BHP Billiton, ENI, PDO, Saudi Aramco, Schlumberger, Shell, Statoil, Total and iRock.
China Materialia has also joined iRock Technologies’ Board of Directors.
Witnessed by Shanghai Shanghai Bureau of Civil Administration officials at a foundation establishment ceremony, China Materialia formally launched the Not-for-Profit Shanghai Strategic Emerging Industries Foundation. The SEIF Foundation is a not-for-profit organization committed to become thought-leader for strategic emerging industries in China, a bridge for China and the World, and a platform for innovation and entrepreneurship. SEIF Foundation promotes China’s technology advancement, venture capital, industrial transformation and economic development.
China Materialia’s portfolio company, ZipLine Medical, Inc. announced today that it has been awarded “2014 Best New Technology In Spine Care” by Orthopedics This Week for the Zip® Surgical Skin Closure device. The award was presented to ZipLine Medical’s President and CEO, John Tighe, at the North America Spine Society’s annual scientific meeting in San Francisco. The Zip® Surgical Skin Closure was selected by a distinguished panel of 5 board-certified orthopedic and spine surgeons on the basis of its originality, clinical relevance (including would the judges use the product themselves) and likelihood of improving patient outcomes.
China Materialia lead a $5.7 million extension round for Campbell California-based Zipline Medical. The financing extension included participation from existing investors RA Capital Management, Claremont Creek Ventures and XSeed Capital. Proceeds from the Series C extension will be used to expand sales and marketing activities.
“The noninvasive Zip® Surgical Skin Closure device is a transformative product with numerous applications across many markets around the world,” said Min Zhou, PhD, co-founder and CEO of China Materialia. “We see that Zip® is bringing significant benefits to patients while reducing hospital cost and infection rate. We are happy to support ZipLine Medical and help its expansion into China market,” added Dr. Zhou, who has joined ZipLine’s board of directors.
China Materialia has added two investment Directors to its team: Mr. Donald Gao and Ms. Michelle Hua.
Before joining China Materialia, Mr. Donald Gao held investment management positions with China New Enterprise Capital based in Beijing, and Global Assets Investment based in silicon valley. Earlier in his career, Donald worked in Citigroup investment banking division, and held diplomatic position as an Economic and Commercial Vice Consul to the USA. Prior to that, Mr. Gao worked in China Ministry of Commerce where he was responsible for Sino-USA bilateral economic cooperation and negotiations in all national level hot button economic issues.
As the opening keynote speaker at the Australia Week’s China innovation and technology symposium in Shanghai, Dr. Min Zhou shared with a packed audience of Australian MNC and start-up companies opportunities and challenges for innovative start-up companies in China.
Dr. Zhou shared China Material’s venture capital model, where China Materialia invests in start-up companies and actively help them to connect with multinational companies in an “open innovation” and “open entrepreneurship” approach. Dr. Zhou also emphasized that it is important for foreign start-up companies coming to China market to embrace “open entrepreneurship” philosophy and really find investors who can bring not only capital, but help companies find partnerships and local resources.
In collaboration with the Anderson Business School of UCLA, China Materialia is organizing an Innovation China 2013 event that includes an Open Innovation Forum on November 15 and an Entrepreneurship Training Day on November 16.
At the inaugural Open Innovation Forum, some of China’s best and most innovative start-ups in the IT, Industrial and Consumer sectors will showcase their companies; open Innovation practitioners will hold candid discussions about their experiences in China and best practices; Law firms and venture capital groups will share their experiences in IP protection and making equity investments in start-ups. It is a great event for MNC companies to learn more about China’s innovation landscape and meet with their peers.
The Event will be held at the world-renown Shanghai World Expo Center that hosted the 2010 World Expo and now reopen with many new exhibitions.
China Materialia has lead a Series A investment in Octadem, a digital spectrometer company with offices in the US, Shanghai and Wuxi.
Founded by a group of “returnees” from the US, Octadem has successfully developed a portable digital spectrophotometer that, when used with accompany reagents, can be used for solution analysis. While bench-top digital spectrophotometer has been around for many years, Octadem’s core technology lies in utilizing inexpensive LED as light sources and proprietary algorithms for calculating spectral curve, eliminating expensive light splitting and filtering lenses, thus dramatically reducing size and cost of the equipment to the point of portability and affordability to target water quality monitoring and consumer health monitoring.
Dr. Patrick Berbon has joined Octadem’s board of directors.